The handbook of biological therapy :: a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology /
Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted fo...
Gespeichert in:
| Weitere Verfasser: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Oxford :
Oxford University Press,
2008.
|
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Zusammenfassung: | Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary. |
| Beschreibung: | 1 online resource (xiv, 155 pages) : illustrations |
| Format: | Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. |
| Bibliographie: | Includes bibliographical references and index. |
| ISBN: | 9780191548970 0191548979 9780191768583 0191768588 1283581272 9781283581271 9786613893727 6613893722 |
Internformat
MARC
| LEADER | 00000cam a2200000 a 4500 | ||
|---|---|---|---|
| 001 | ZDB-4-EBA-ocn801405277 | ||
| 003 | OCoLC | ||
| 005 | 20241004212047.0 | ||
| 006 | m o d | ||
| 007 | cr cnu---unuuu | ||
| 008 | 120723s2008 enka ob 001 0 eng d | ||
| 010 | |z 2009277297 | ||
| 040 | |a N$T |b eng |e pn |c N$T |d E7B |d OCLCQ |d OCLCE |d OCLCQ |d NLGGC |d YDXCP |d EBLCP |d IDEBK |d DEBSZ |d OCLCQ |d CUV |d OCLCQ |d D6H |d AZK |d STBDS |d AGLDB |d MOR |d CCO |d PIFAG |d ZCU |d OCLCQ |d MERUC |d OCLCQ |d U3W |d STF |d OCLCF |d OCLCO |d VNS |d WRM |d OCLCQ |d VTS |d COCUF |d NRAMU |d ICG |d INT |d VT2 |d TOF |d OCLCO |d AU@ |d OCLCO |d OCLCQ |d WYU |d OCLCO |d OCLCA |d REC |d OCLCQ |d OCLCO |d DKC |d OCLCO |d OCLCQ |d CEF |d UX1 |d OCLCQ |d HS0 |d UWK |d ADU |d LIP |d OCLCQ |d OCLCA |d OCLCQ |d OCLCA |d UKCRE |d AJS |d OCLCQ |d OCLCO |d CNNOR |d OCLCQ |d REDDC |d OCLCO |d OCLCQ |d OCLCO | ||
| 015 | |a GBA898115 |2 bnb | ||
| 016 | 7 | |a 014691058 |2 Uk | |
| 019 | |a 664763575 |a 681553825 |a 801363553 |a 961629833 |a 962647980 |a 967267761 |a 978671446 |a 978898472 |a 988493085 |a 991986815 |a 1016977064 |a 1018056497 |a 1037680991 |a 1038046306 |a 1038671137 |a 1042912192 |a 1043657241 |a 1045493288 |a 1047923607 |a 1053530757 |a 1055317289 |a 1065415915 |a 1065943574 |a 1080551323 |a 1081225048 |a 1100827629 |a 1101711071 |a 1109347794 |a 1110384225 |a 1112838591 |a 1119028015 |a 1119105759 |a 1120898120 |a 1135590499 |a 1153501206 |a 1157968374 |a 1162193876 |a 1178722048 |a 1183975397 |a 1228600262 |a 1249173083 |a 1257358611 |a 1257372835 |a 1290079556 |a 1297041316 |a 1300542608 |a 1351293063 |a 1357384586 |a 1397471011 |a 1434172573 | ||
| 020 | |a 9780191548970 |q (electronic bk.) | ||
| 020 | |a 0191548979 |q (electronic bk.) | ||
| 020 | |a 9780191768583 | ||
| 020 | |a 0191768588 | ||
| 020 | |a 1283581272 | ||
| 020 | |a 9781283581271 | ||
| 020 | |a 9786613893727 | ||
| 020 | |a 6613893722 | ||
| 020 | |z 9780199208166 | ||
| 020 | |z 0199208166 | ||
| 035 | |a (OCoLC)801405277 |z (OCoLC)664763575 |z (OCoLC)681553825 |z (OCoLC)801363553 |z (OCoLC)961629833 |z (OCoLC)962647980 |z (OCoLC)967267761 |z (OCoLC)978671446 |z (OCoLC)978898472 |z (OCoLC)988493085 |z (OCoLC)991986815 |z (OCoLC)1016977064 |z (OCoLC)1018056497 |z (OCoLC)1037680991 |z (OCoLC)1038046306 |z (OCoLC)1038671137 |z (OCoLC)1042912192 |z (OCoLC)1043657241 |z (OCoLC)1045493288 |z (OCoLC)1047923607 |z (OCoLC)1053530757 |z (OCoLC)1055317289 |z (OCoLC)1065415915 |z (OCoLC)1065943574 |z (OCoLC)1080551323 |z (OCoLC)1081225048 |z (OCoLC)1100827629 |z (OCoLC)1101711071 |z (OCoLC)1109347794 |z (OCoLC)1110384225 |z (OCoLC)1112838591 |z (OCoLC)1119028015 |z (OCoLC)1119105759 |z (OCoLC)1120898120 |z (OCoLC)1135590499 |z (OCoLC)1153501206 |z (OCoLC)1157968374 |z (OCoLC)1162193876 |z (OCoLC)1178722048 |z (OCoLC)1183975397 |z (OCoLC)1228600262 |z (OCoLC)1249173083 |z (OCoLC)1257358611 |z (OCoLC)1257372835 |z (OCoLC)1290079556 |z (OCoLC)1297041316 |z (OCoLC)1300542608 |z (OCoLC)1351293063 |z (OCoLC)1357384586 |z (OCoLC)1397471011 |z (OCoLC)1434172573 | ||
| 037 | |n Title subscribed to via ProQuest Academic Complete | ||
| 042 | |a dlr | ||
| 050 | 4 | |a QH345 |b .H348 2008eb | |
| 060 | 4 | |a 2009 C-448 | |
| 060 | 4 | |a QW 630 |b H2356 2008 | |
| 072 | 7 | |a MED |x 071000 |2 bisacsh | |
| 082 | 7 | |a 615.7 |2 22 | |
| 049 | |a MAIN | ||
| 245 | 0 | 4 | |a The handbook of biological therapy : |b a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / |c Bruce Kirkham [and others]. |
| 260 | |a Oxford : |b Oxford University Press, |c 2008. | ||
| 300 | |a 1 online resource (xiv, 155 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent | ||
| 337 | |a computer |b c |2 rdamedia | ||
| 338 | |a online resource |b cr |2 rdacarrier | ||
| 347 | |a data file | ||
| 504 | |a Includes bibliographical references and index. | ||
| 588 | 0 | |a Print version record. | |
| 506 | |3 Use copy |f Restrictions unspecified |2 star |5 MiAaHDL | ||
| 533 | |a Electronic reproduction. |b [Place of publication not identified] : |c HathiTrust Digital Library, |d 2010. |5 MiAaHDL | ||
| 538 | |a Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. |u http://purl.oclc.org/DLF/benchrepro0212 |5 MiAaHDL | ||
| 583 | 1 | |a digitized |c 2010 |h HathiTrust Digital Library |l committed to preserve |2 pda |5 MiAaHDL | |
| 505 | 0 | |a Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation. | |
| 505 | 8 | |a RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis. | |
| 505 | 8 | |a Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V. | |
| 520 | |a Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary. | ||
| 546 | |a English. | ||
| 650 | 0 | |a Biological products |x Therapeutic use. |0 http://id.loc.gov/authorities/subjects/sh90001152 | |
| 650 | 0 | |a Tumor necrosis factor |x Inhibitors. | |
| 650 | 1 | 2 | |a Tumor Necrosis Factor-alpha |x therapeutic use |
| 650 | 2 | 2 | |a Gastrointestinal Diseases |x therapy |
| 650 | 2 | 2 | |a Rheumatic Diseases |x therapy |
| 650 | 2 | 2 | |a Skin Diseases |x therapy |
| 650 | 2 | |a Biological Therapy |0 https://id.nlm.nih.gov/mesh/D001691 | |
| 650 | 6 | |a Biothérapie. | |
| 650 | 6 | |a Tractus gastro-intestinal |x Maladies |x Traitement. | |
| 650 | 7 | |a MEDICAL |x Pharmacology. |2 bisacsh | |
| 650 | 7 | |a Biological products |x Therapeutic use |2 fast | |
| 700 | 1 | |a Kirkham, Bruce. |0 http://id.loc.gov/authorities/names/nb2009001507 | |
| 776 | 0 | 8 | |i Print version: |t Handbook of biological therapy. |d Oxford : Oxford University Press, 2008 |z 9780199208166 |w (DLC) 2009277297 |w (OCoLC)233545995 |
| 856 | 4 | 0 | |l FWS01 |p ZDB-4-EBA |q FWS_PDA_EBA |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467497 |3 Volltext |
| 938 | |a ProQuest Ebook Central |b EBLB |n EBL975668 | ||
| 938 | |a ebrary |b EBRY |n ebr10581739 | ||
| 938 | |a EBSCOhost |b EBSC |n 467497 | ||
| 938 | |a ProQuest MyiLibrary Digital eBook Collection |b IDEB |n 389372 | ||
| 938 | |a Oxford University Press USA |b OUPR |n EDZ0000128785 | ||
| 938 | |a YBP Library Services |b YANK |n 12890309 | ||
| 938 | |a YBP Library Services |b YANK |n 9315947 | ||
| 994 | |a 92 |b GEBAY | ||
| 912 | |a ZDB-4-EBA | ||
| 049 | |a DE-863 | ||
Datensatz im Suchindex
| DE-BY-FWS_katkey | ZDB-4-EBA-ocn801405277 |
|---|---|
| _version_ | 1816882201161105408 |
| adam_text | |
| any_adam_object | |
| author2 | Kirkham, Bruce |
| author2_role | |
| author2_variant | b k bk |
| author_GND | http://id.loc.gov/authorities/names/nb2009001507 |
| author_facet | Kirkham, Bruce |
| author_sort | Kirkham, Bruce |
| building | Verbundindex |
| bvnumber | localFWS |
| callnumber-first | Q - Science |
| callnumber-label | QH345 |
| callnumber-raw | QH345 .H348 2008eb |
| callnumber-search | QH345 .H348 2008eb |
| callnumber-sort | QH 3345 H348 42008EB |
| callnumber-subject | QH - Natural History and Biology |
| collection | ZDB-4-EBA |
| contents | Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation. RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis. Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V. |
| ctrlnum | (OCoLC)801405277 |
| dewey-full | 615.7 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.7 |
| dewey-search | 615.7 |
| dewey-sort | 3615.7 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>07830cam a2200865 a 4500</leader><controlfield tag="001">ZDB-4-EBA-ocn801405277</controlfield><controlfield tag="003">OCoLC</controlfield><controlfield tag="005">20241004212047.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr cnu---unuuu</controlfield><controlfield tag="008">120723s2008 enka ob 001 0 eng d</controlfield><datafield tag="010" ind1=" " ind2=" "><subfield code="z"> 2009277297</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">N$T</subfield><subfield code="b">eng</subfield><subfield code="e">pn</subfield><subfield code="c">N$T</subfield><subfield code="d">E7B</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCE</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">NLGGC</subfield><subfield code="d">YDXCP</subfield><subfield code="d">EBLCP</subfield><subfield code="d">IDEBK</subfield><subfield code="d">DEBSZ</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">CUV</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">D6H</subfield><subfield code="d">AZK</subfield><subfield code="d">STBDS</subfield><subfield code="d">AGLDB</subfield><subfield code="d">MOR</subfield><subfield code="d">CCO</subfield><subfield code="d">PIFAG</subfield><subfield code="d">ZCU</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">MERUC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">U3W</subfield><subfield code="d">STF</subfield><subfield code="d">OCLCF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">VNS</subfield><subfield code="d">WRM</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">VTS</subfield><subfield code="d">COCUF</subfield><subfield code="d">NRAMU</subfield><subfield code="d">ICG</subfield><subfield code="d">INT</subfield><subfield code="d">VT2</subfield><subfield code="d">TOF</subfield><subfield code="d">OCLCO</subfield><subfield code="d">AU@</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">WYU</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCA</subfield><subfield code="d">REC</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">DKC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">CEF</subfield><subfield code="d">UX1</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">HS0</subfield><subfield code="d">UWK</subfield><subfield code="d">ADU</subfield><subfield code="d">LIP</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCA</subfield><subfield code="d">UKCRE</subfield><subfield code="d">AJS</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield><subfield code="d">CNNOR</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">REDDC</subfield><subfield code="d">OCLCO</subfield><subfield code="d">OCLCQ</subfield><subfield code="d">OCLCO</subfield></datafield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">GBA898115</subfield><subfield code="2">bnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">014691058</subfield><subfield code="2">Uk</subfield></datafield><datafield tag="019" ind1=" " ind2=" "><subfield code="a">664763575</subfield><subfield code="a">681553825</subfield><subfield code="a">801363553</subfield><subfield code="a">961629833</subfield><subfield code="a">962647980</subfield><subfield code="a">967267761</subfield><subfield code="a">978671446</subfield><subfield code="a">978898472</subfield><subfield code="a">988493085</subfield><subfield code="a">991986815</subfield><subfield code="a">1016977064</subfield><subfield code="a">1018056497</subfield><subfield code="a">1037680991</subfield><subfield code="a">1038046306</subfield><subfield code="a">1038671137</subfield><subfield code="a">1042912192</subfield><subfield code="a">1043657241</subfield><subfield code="a">1045493288</subfield><subfield code="a">1047923607</subfield><subfield code="a">1053530757</subfield><subfield code="a">1055317289</subfield><subfield code="a">1065415915</subfield><subfield code="a">1065943574</subfield><subfield code="a">1080551323</subfield><subfield code="a">1081225048</subfield><subfield code="a">1100827629</subfield><subfield code="a">1101711071</subfield><subfield code="a">1109347794</subfield><subfield code="a">1110384225</subfield><subfield code="a">1112838591</subfield><subfield code="a">1119028015</subfield><subfield code="a">1119105759</subfield><subfield code="a">1120898120</subfield><subfield code="a">1135590499</subfield><subfield code="a">1153501206</subfield><subfield code="a">1157968374</subfield><subfield code="a">1162193876</subfield><subfield code="a">1178722048</subfield><subfield code="a">1183975397</subfield><subfield code="a">1228600262</subfield><subfield code="a">1249173083</subfield><subfield code="a">1257358611</subfield><subfield code="a">1257372835</subfield><subfield code="a">1290079556</subfield><subfield code="a">1297041316</subfield><subfield code="a">1300542608</subfield><subfield code="a">1351293063</subfield><subfield code="a">1357384586</subfield><subfield code="a">1397471011</subfield><subfield code="a">1434172573</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780191548970</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0191548979</subfield><subfield code="q">(electronic bk.)</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780191768583</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0191768588</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1283581272</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781283581271</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9786613893727</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">6613893722</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">9780199208166</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="z">0199208166</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)801405277</subfield><subfield code="z">(OCoLC)664763575</subfield><subfield code="z">(OCoLC)681553825</subfield><subfield code="z">(OCoLC)801363553</subfield><subfield code="z">(OCoLC)961629833</subfield><subfield code="z">(OCoLC)962647980</subfield><subfield code="z">(OCoLC)967267761</subfield><subfield code="z">(OCoLC)978671446</subfield><subfield code="z">(OCoLC)978898472</subfield><subfield code="z">(OCoLC)988493085</subfield><subfield code="z">(OCoLC)991986815</subfield><subfield code="z">(OCoLC)1016977064</subfield><subfield code="z">(OCoLC)1018056497</subfield><subfield code="z">(OCoLC)1037680991</subfield><subfield code="z">(OCoLC)1038046306</subfield><subfield code="z">(OCoLC)1038671137</subfield><subfield code="z">(OCoLC)1042912192</subfield><subfield code="z">(OCoLC)1043657241</subfield><subfield code="z">(OCoLC)1045493288</subfield><subfield code="z">(OCoLC)1047923607</subfield><subfield code="z">(OCoLC)1053530757</subfield><subfield code="z">(OCoLC)1055317289</subfield><subfield code="z">(OCoLC)1065415915</subfield><subfield code="z">(OCoLC)1065943574</subfield><subfield code="z">(OCoLC)1080551323</subfield><subfield code="z">(OCoLC)1081225048</subfield><subfield code="z">(OCoLC)1100827629</subfield><subfield code="z">(OCoLC)1101711071</subfield><subfield code="z">(OCoLC)1109347794</subfield><subfield code="z">(OCoLC)1110384225</subfield><subfield code="z">(OCoLC)1112838591</subfield><subfield code="z">(OCoLC)1119028015</subfield><subfield code="z">(OCoLC)1119105759</subfield><subfield code="z">(OCoLC)1120898120</subfield><subfield code="z">(OCoLC)1135590499</subfield><subfield code="z">(OCoLC)1153501206</subfield><subfield code="z">(OCoLC)1157968374</subfield><subfield code="z">(OCoLC)1162193876</subfield><subfield code="z">(OCoLC)1178722048</subfield><subfield code="z">(OCoLC)1183975397</subfield><subfield code="z">(OCoLC)1228600262</subfield><subfield code="z">(OCoLC)1249173083</subfield><subfield code="z">(OCoLC)1257358611</subfield><subfield code="z">(OCoLC)1257372835</subfield><subfield code="z">(OCoLC)1290079556</subfield><subfield code="z">(OCoLC)1297041316</subfield><subfield code="z">(OCoLC)1300542608</subfield><subfield code="z">(OCoLC)1351293063</subfield><subfield code="z">(OCoLC)1357384586</subfield><subfield code="z">(OCoLC)1397471011</subfield><subfield code="z">(OCoLC)1434172573</subfield></datafield><datafield tag="037" ind1=" " ind2=" "><subfield code="n">Title subscribed to via ProQuest Academic Complete</subfield></datafield><datafield tag="042" ind1=" " ind2=" "><subfield code="a">dlr</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">QH345</subfield><subfield code="b">.H348 2008eb</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">2009 C-448</subfield></datafield><datafield tag="060" ind1=" " ind2="4"><subfield code="a">QW 630</subfield><subfield code="b">H2356 2008</subfield></datafield><datafield tag="072" ind1=" " ind2="7"><subfield code="a">MED</subfield><subfield code="x">071000</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="082" ind1="7" ind2=" "><subfield code="a">615.7</subfield><subfield code="2">22</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">MAIN</subfield></datafield><datafield tag="245" ind1="0" ind2="4"><subfield code="a">The handbook of biological therapy :</subfield><subfield code="b">a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology /</subfield><subfield code="c">Bruce Kirkham [and others].</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Oxford :</subfield><subfield code="b">Oxford University Press,</subfield><subfield code="c">2008.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (xiv, 155 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="347" ind1=" " ind2=" "><subfield code="a">data file</subfield></datafield><datafield tag="504" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references and index.</subfield></datafield><datafield tag="588" ind1="0" ind2=" "><subfield code="a">Print version record.</subfield></datafield><datafield tag="506" ind1=" " ind2=" "><subfield code="3">Use copy</subfield><subfield code="f">Restrictions unspecified</subfield><subfield code="2">star</subfield><subfield code="5">MiAaHDL</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="a">Electronic reproduction.</subfield><subfield code="b">[Place of publication not identified] :</subfield><subfield code="c">HathiTrust Digital Library,</subfield><subfield code="d">2010.</subfield><subfield code="5">MiAaHDL</subfield></datafield><datafield tag="538" ind1=" " ind2=" "><subfield code="a">Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002.</subfield><subfield code="u">http://purl.oclc.org/DLF/benchrepro0212</subfield><subfield code="5">MiAaHDL</subfield></datafield><datafield tag="583" ind1="1" ind2=" "><subfield code="a">digitized</subfield><subfield code="c">2010</subfield><subfield code="h">HathiTrust Digital Library</subfield><subfield code="l">committed to preserve</subfield><subfield code="2">pda</subfield><subfield code="5">MiAaHDL</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis.</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Biological products</subfield><subfield code="x">Therapeutic use.</subfield><subfield code="0">http://id.loc.gov/authorities/subjects/sh90001152</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Tumor necrosis factor</subfield><subfield code="x">Inhibitors.</subfield></datafield><datafield tag="650" ind1="1" ind2="2"><subfield code="a">Tumor Necrosis Factor-alpha</subfield><subfield code="x">therapeutic use</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Gastrointestinal Diseases</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Rheumatic Diseases</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1="2" ind2="2"><subfield code="a">Skin Diseases</subfield><subfield code="x">therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="2"><subfield code="a">Biological Therapy</subfield><subfield code="0">https://id.nlm.nih.gov/mesh/D001691</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Biothérapie.</subfield></datafield><datafield tag="650" ind1=" " ind2="6"><subfield code="a">Tractus gastro-intestinal</subfield><subfield code="x">Maladies</subfield><subfield code="x">Traitement.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL</subfield><subfield code="x">Pharmacology.</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Biological products</subfield><subfield code="x">Therapeutic use</subfield><subfield code="2">fast</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Kirkham, Bruce.</subfield><subfield code="0">http://id.loc.gov/authorities/names/nb2009001507</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Print version:</subfield><subfield code="t">Handbook of biological therapy.</subfield><subfield code="d">Oxford : Oxford University Press, 2008</subfield><subfield code="z">9780199208166</subfield><subfield code="w">(DLC) 2009277297</subfield><subfield code="w">(OCoLC)233545995</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="l">FWS01</subfield><subfield code="p">ZDB-4-EBA</subfield><subfield code="q">FWS_PDA_EBA</subfield><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467497</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest Ebook Central</subfield><subfield code="b">EBLB</subfield><subfield code="n">EBL975668</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ebrary</subfield><subfield code="b">EBRY</subfield><subfield code="n">ebr10581739</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">EBSCOhost</subfield><subfield code="b">EBSC</subfield><subfield code="n">467497</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">ProQuest MyiLibrary Digital eBook Collection</subfield><subfield code="b">IDEB</subfield><subfield code="n">389372</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">Oxford University Press USA</subfield><subfield code="b">OUPR</subfield><subfield code="n">EDZ0000128785</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">12890309</subfield></datafield><datafield tag="938" ind1=" " ind2=" "><subfield code="a">YBP Library Services</subfield><subfield code="b">YANK</subfield><subfield code="n">9315947</subfield></datafield><datafield tag="994" ind1=" " ind2=" "><subfield code="a">92</subfield><subfield code="b">GEBAY</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-EBA</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-863</subfield></datafield></record></collection> |
| id | ZDB-4-EBA-ocn801405277 |
| illustrated | Illustrated |
| indexdate | 2024-11-27T13:24:51Z |
| institution | BVB |
| isbn | 9780191548970 0191548979 9780191768583 0191768588 1283581272 9781283581271 9786613893727 6613893722 |
| language | English |
| oclc_num | 801405277 |
| open_access_boolean | |
| owner | MAIN DE-863 DE-BY-FWS |
| owner_facet | MAIN DE-863 DE-BY-FWS |
| physical | 1 online resource (xiv, 155 pages) : illustrations |
| psigel | ZDB-4-EBA |
| publishDate | 2008 |
| publishDateSearch | 2008 |
| publishDateSort | 2008 |
| publisher | Oxford University Press, |
| record_format | marc |
| spelling | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / Bruce Kirkham [and others]. Oxford : Oxford University Press, 2008. 1 online resource (xiv, 155 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier data file Includes bibliographical references and index. Print version record. Use copy Restrictions unspecified star MiAaHDL Electronic reproduction. [Place of publication not identified] : HathiTrust Digital Library, 2010. MiAaHDL Master and use copy. Digital master created according to Benchmark for Faithful Digital Reproductions of Monographs and Serials, Version 1. Digital Library Federation, December 2002. http://purl.oclc.org/DLF/benchrepro0212 MiAaHDL digitized 2010 HathiTrust Digital Library committed to preserve pda MiAaHDL Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation. RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis. Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V. Drugs produced by molecular biological techniques, called the 'biologics', differ from the usual chemical medications. Their optimum use, and the detection and managemenet of adverse events, pose a significant challenge to the clinician. Licences for new biologics continue to be granted for the likes of rituximab, abatacept and certocizumals pegol. Intensive research is also defining new areas in which these drugs will be used in the future, increasing the number of practitionersusing biologics. As the use of these drugs increases around the world, so the level of information needed by primary. English. Biological products Therapeutic use. http://id.loc.gov/authorities/subjects/sh90001152 Tumor necrosis factor Inhibitors. Tumor Necrosis Factor-alpha therapeutic use Gastrointestinal Diseases therapy Rheumatic Diseases therapy Skin Diseases therapy Biological Therapy https://id.nlm.nih.gov/mesh/D001691 Biothérapie. Tractus gastro-intestinal Maladies Traitement. MEDICAL Pharmacology. bisacsh Biological products Therapeutic use fast Kirkham, Bruce. http://id.loc.gov/authorities/names/nb2009001507 Print version: Handbook of biological therapy. Oxford : Oxford University Press, 2008 9780199208166 (DLC) 2009277297 (OCoLC)233545995 FWS01 ZDB-4-EBA FWS_PDA_EBA https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467497 Volltext |
| spellingShingle | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / Preface; Foreword; Contents; TNF -- tumour necrosis factor [alpha]; Mode of action of anti-TNF; TNF-blocking drugs in clinical use; TNF-blocking drugs not in clinical use; Section 1 TNF-blocker safety; Increased risk of infection; Tuberculosis; Opportunistic infections; Injection-site reactions; Allergic, hypersensitivity reactions, anaphylactic responses; Psoriasis; Infusion reactions (infliximab); Malignancy and lymphoproliferative conditions; Drug-induced lupus-like reactions; Anti-drug antibodies (immunogenicity); Congestive heart failure; Neurological; Hepatobiliary; Use in pregnancy; Lactation. RespiratoryVaccinations; Use of TNF-blockers with other medications; Haematological; Postmarketing safety experience in Crohn's disease; Section 2 Rheumatology; Rheumatoid arthritis; Other rheumatological conditions; TNF-blocking therapy in ankylosing spondylitis and psoriatic arthritis; Ankylosing spondylitis; Psoriatic arthritis; Adalimumab (Humira); Etanercept (Enbrel); Infliximab (Remicade); Certolizumab pegol (Cimzia); Abatacept (Orencia); Anakinra (Kineret); B-cell depletion: Rituximab (Rituxan® [USA], MabThera® [Europe, Asia, South America]); Section 3 Dermatology; Psoriasis. Approaches to managementAssessing disease severity; Important differences between psoriasis and rheumatoid arthritis; Biological therapy for psoriasis; Etanercept (Enbrel); Infliximab (Remicade); Adalimumab (Humira); Efalizumab (Raptiva); Alefacept (Amevive); Section 4 Gastroenterology; Biological therapy in inflammatory bowel disease and Crohn's disease; Adalimumab (Humira); Infliximab (Remicade); Natalizumab (Tysabri); Certolizumab pegol (Cimzia); Index; A; B; C; D; E; G; H; I; K; L; M; N; O; P; R; S; T; U; V. Biological products Therapeutic use. http://id.loc.gov/authorities/subjects/sh90001152 Tumor necrosis factor Inhibitors. Tumor Necrosis Factor-alpha therapeutic use Gastrointestinal Diseases therapy Rheumatic Diseases therapy Skin Diseases therapy Biological Therapy https://id.nlm.nih.gov/mesh/D001691 Biothérapie. Tractus gastro-intestinal Maladies Traitement. MEDICAL Pharmacology. bisacsh Biological products Therapeutic use fast |
| subject_GND | http://id.loc.gov/authorities/subjects/sh90001152 https://id.nlm.nih.gov/mesh/D001691 |
| title | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / |
| title_auth | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / |
| title_exact_search | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / |
| title_full | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / Bruce Kirkham [and others]. |
| title_fullStr | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / Bruce Kirkham [and others]. |
| title_full_unstemmed | The handbook of biological therapy : a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / Bruce Kirkham [and others]. |
| title_short | The handbook of biological therapy : |
| title_sort | handbook of biological therapy a guide to the use and safety of biological therapies in rheumatology dermatology and gastroenterology |
| title_sub | a guide to the use and safety of biological therapies in rheumatology, dermatology, and gastroenterology / |
| topic | Biological products Therapeutic use. http://id.loc.gov/authorities/subjects/sh90001152 Tumor necrosis factor Inhibitors. Tumor Necrosis Factor-alpha therapeutic use Gastrointestinal Diseases therapy Rheumatic Diseases therapy Skin Diseases therapy Biological Therapy https://id.nlm.nih.gov/mesh/D001691 Biothérapie. Tractus gastro-intestinal Maladies Traitement. MEDICAL Pharmacology. bisacsh Biological products Therapeutic use fast |
| topic_facet | Biological products Therapeutic use. Tumor necrosis factor Inhibitors. Tumor Necrosis Factor-alpha therapeutic use Gastrointestinal Diseases therapy Rheumatic Diseases therapy Skin Diseases therapy Biological Therapy Biothérapie. Tractus gastro-intestinal Maladies Traitement. MEDICAL Pharmacology. Biological products Therapeutic use |
| url | https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=467497 |
| work_keys_str_mv | AT kirkhambruce thehandbookofbiologicaltherapyaguidetotheuseandsafetyofbiologicaltherapiesinrheumatologydermatologyandgastroenterology AT kirkhambruce handbookofbiologicaltherapyaguidetotheuseandsafetyofbiologicaltherapiesinrheumatologydermatologyandgastroenterology |